| ID | 1112 |
| Name of the vaccine | Bivalent (Equine) |
| Microbe | Bacteria |
| Disease name | Botulism |
| Name of bacteria | Clostridium botulinum |
| Type of vaccine | Toxoid |
| Nucleic acid content | DNA |
| Age | NA |
| Description of the vaccine | Botulism antitoxin bivalent (Equine) types A and B. |
| Name of the manufacturer | Sanofi Pasteur Limited |
| Name of the manufacturing country | Canada |
| Year of manufacture | NA |
| Clinical Phase status | Approved |
| Bacterial strain | Gram-positive anaerobic bacterium. |
| Efficacy | NA |
| Vaccine formulation | NA |
| Dosage | For prevention - 1,500-7,500 IU of type A and 1,100-5,500 IU of type B .
For treatment - 7,500 IU of type A and 5,500 IU of type B. |
| Mechanism of action | NA |
| Route of administration | Intravenous |
| Indications | For prevention or treatment of Botulism types A and B. |
| Export | NA |
| Approval | US FDA |
| Adjuvant | NA |
| Repurposing | NA |
| Side effects of vaccine | Anaphylactic reactions, chilly sensation, slight dyspnoea, fever, urticaria, arthritis and lymphadenopathy. |
| Post vaccination | NA |
| Dose type | Combination doses |
| Interspecies transfer | NA |
| PubMed identifier | NA |
| Clinical trial number | NA |
| Reference | https://www.fda.gov/media/78196/download#:~:text=Botulism%20Antitoxin%20Bivalent%20(Equine)%2C,phenol%200.4%25%20as%20a%20preservative. |
| Other name | NA |
| Additional Links | NA
|